Alain Godard Sells 6,125 Shares of Calyxt Inc (CLXT) Stock

Calyxt Inc (NASDAQ:CLXT) Director Alain Godard sold 6,125 shares of the company’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $20.70, for a total value of $126,787.50. Following the completion of the transaction, the director now directly owns 45,325 shares in the company, valued at approximately $938,227.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Alain Godard also recently made the following trade(s):

  • On Thursday, February 22nd, Alain Godard sold 19,825 shares of Calyxt stock. The shares were sold at an average price of $19.65, for a total value of $389,561.25.

Shares of Calyxt Inc (NASDAQ CLXT) opened at $19.52 on Friday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 12.41 and a current ratio of 12.41. Calyxt Inc has a one year low of $9.26 and a one year high of $31.89. The stock has a market cap of $541.68 and a price-to-earnings ratio of -21.93.

A number of large investors have recently made changes to their positions in the business. BlackRock Inc. raised its stake in Calyxt by 102.8% during the 4th quarter. BlackRock Inc. now owns 740,010 shares of the company’s stock valued at $16,302,000 after purchasing an additional 375,137 shares during the period. Wells Fargo & Company MN raised its stake in Calyxt by 1,421.9% during the 4th quarter. Wells Fargo & Company MN now owns 30,788 shares of the company’s stock valued at $678,000 after purchasing an additional 28,765 shares during the period. Bank of New York Mellon Corp acquired a new stake in Calyxt during the 3rd quarter valued at $542,000. Deutsche Bank AG raised its stake in Calyxt by 151.3% during the 4th quarter. Deutsche Bank AG now owns 18,378 shares of the company’s stock valued at $404,000 after purchasing an additional 11,064 shares during the period. Finally, Goldman Sachs Group Inc. acquired a new stake in Calyxt during the 4th quarter valued at $330,000. 22.59% of the stock is currently owned by institutional investors.

Several research firms have issued reports on CLXT. Zacks Investment Research raised Calyxt from a “sell” rating to a “hold” rating in a report on Tuesday, November 28th. BMO Capital Markets began coverage on Calyxt in a report on Monday, October 30th. They issued an “outperform” rating and a $32.00 price target on the stock. Jefferies Group upped their price target on Calyxt to $27.00 and gave the company a “buy” rating in a report on Wednesday, November 1st. Ladenburg Thalmann Financial Services began coverage on Calyxt in a report on Wednesday, December 20th. They issued a “buy” rating and a $34.25 price target on the stock. Finally, Citigroup dropped their price target on Calyxt from $27.00 to $22.00 and set a “neutral” rating on the stock in a report on Thursday, November 16th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $29.05.

TRADEMARK VIOLATION NOTICE: This story was posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.thelincolnianonline.com/2018/02/24/alain-godard-sells-6125-shares-of-calyxt-inc-clxt-stock.html.

About Calyxt

Calyxt, Inc is a food and agriculture company. The Company is focused on delivering healthier specialty food ingredients, such as healthier oils and high fiber wheat, for consumers and agriculturally advantageous crop traits, such as herbicide tolerance to farmers. The Company also combines gene-editing technology and technical that enables to edit a plant genome to elicit the desired traits and characteristics.

Receive News & Ratings for Calyxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calyxt and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply